When it comes to readiness for the adoption of artificial intelligence (AI) among big pharmaceutical companies, Swiss company Roche was at the top, as of August 2023. According to an index, calculated based on talent, innovation and execution, Roche had the highest score. In many cases, big pharma companies build up their AI readiness by acquisition of smaller, but extremely innovative and technology-driven companies.

As of 2024, GSK (GlaxoSmithKline) - with 3.72 - had the second-highest total score. It was the first time in 16 years that GSK was not ranked first. The Access to Medicine Index is an independent initiative that ranks the world’s 20 largest companies according to their efforts to make their products more available, affordable and accessible in developing countries, highlighting policy and practice that either facilitate or hinder access to medicine.

This statistic depicts the pharmaceutical company ranking based on product donations in developing countries as of 2024, according to the Access to Medicine Index. In that year, the company with the highest score in the product delivery category in these countries was GSK, scoring 3.77 points. Product delivery includes, among others, patent transparency and sharing of intellectual property assets.

Snapshot img

What is the Artificial Intelligence In Biotechnology Market Size?

The artificial intelligence in biotechnology market size is forecast to increase by USD 4.46 billion, at a CAGR of 19% between 2024 and 2029. Artificial Intelligence (AI) is revolutionizing the biotechnology industry by enhancing research and development processes, enabling accurate diagnoses, and improving productivity. Key growth factors fueling the market include substantial investments in biotechnology advancements and strategic collaborations between industry players and tech companies. However, the high initial cost of implementing AI solutions remains a challenge for smaller organizations. The market is expected to witness significant growth due to the increasing adoption of AI in areas such as drug discovery, genetic research, and agricultural technology. Furthermore, advancements in machine learning algorithms and natural language processing are enabling more precise and efficient data analysis, leading to new discoveries and innovations. Overall, the integration of AI in biotechnology is transforming the industry and offering numerous opportunities for growth.

What will be the size of the Market during the forecast period?

Request Free Artificial Intelligence In Biotechnology Market Sample

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.

Application

  Drug discovery and development
  Clinical trials and optimization
  Medical imaging
  Diagnostics
  Others


End-user

  Pharmaceutical companies
  Biotechnology companies
  Contract research organization (CRO)
  Healthcare providers
  Others


Geography

  North America

    US


  Europe

    Germany
    UK


  APAC

    China
    India
    Japan
    South Korea


  South America

    Brazil


  Middle East and Africa

Which is the largest segment driving market growth?

The drug discovery and development segment is estimated to witness significant growth during the forecast period. The market is experiencing significant growth, particularly in drug discovery and development. AI technologies are transforming the drug discovery process by increasing accuracy and efficiency in identifying potential drug candidates.

Get a glance at the market share of various regions. Download the PDF Sample

The drug discovery and development segment was valued at USD 522.60 million in 2019. AI applications in biotechnology extend beyond drug discovery, including compound screening, personalized medicine, and environmental factors analysis. This growth is driven by the increasing demand for personalized treatments, the need for faster drug development, and the potential for AI to revolutionize various applications in biotech and pharmaceuticals.

Which region is leading the market?

For more insights on the market share of various regions, Request Free Sample

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The North American region leads the global artificial intelligence (AI) market in biotechnology due to substantial investments, strategic collaborations, and technological advancements. With a strong infrastructure and a strong focus on innovation, the region is at the forefront of adopting and developing AI-driven biotechnological solutions. For example, in March 2023, Predictive Oncology partnered with Integra Therapeutics to enhance gene editing capabilities for cancer therapies. This collaboration leverages Predictive Oncology's expertise in protein expression to advance gene editing techniques, aiming to develop more effective cancer treatments. The partnership in Minnesota highlights the region's commitment to pioneering cancer research and therapeutic development through AI technology. In the life sciences sector, AI is utilized to analyze large datasets of genetic information, improve treatment outcomes, and increase productivity. Key players in the market include leading research institutions and biotechnology companies.

How do company ranking index and market positioning come to your aid?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Abbott Laboratories - The company offers artificial intelligence in biotechnology solutions that include AI-driven medical imaging and predictive analytics for identifying individuals at risk of heart attacks.

Technavio provides the ranking index for the top 20 companies along with insights on the market

As of Q1 2023, there were approximately 800 companies involved in drug discovery with artificial intelligence (AI). Far more than half of all these companies originated from the United States. The European Union ranked second with around 17 percent of these companies located within its member states.

In 2024, Puls earned more than *** billion Russian rubles, listing first in the ranking of pharmaceutical distributors across Russia. Protek ranked second, with a sales value of over *** billion Russian rubles.

In 2024, the ranking of pharmaceutical producers in Russia was led by Pharmstandard, whose sales reached approximately *** million packs. The revenue of Ozon was the second highest, measuring at over 177 million packs. Several international brands, including Nizhpharm, Obnovlenie MPC, and OTC Pharm ceased advertising operations in Russia in response to its invasion of Ukraine in 2024.

In 2024, the United States was the largest market for pharmaceutical product exports from ASEAN, importing approximately 15.5 billion U.S. dollars' worth of pharmaceutical products. Switzerland ranked second, with pharmaceutical imports from ASEAN totaling around 2.1 billion U.S. dollars.

The revenue ranking in the otc pharmaceuticals market is led by the United States with **** billion U.S. dollars, while China is following with **** billion U.S. dollars. In contrast, Sweden is at the bottom of the ranking with ***** million U.S. dollars, showing a difference of **** billion U.S. dollars to the United States. Find other insights concerning similar markets and segments, such as a ranking by country regarding revenue in the skin treatment segment of the OTC pharmaceuticals market and a ranking of subsegments in Asia regarding revenue in the OTC Pharmaceuticals market as a whole. The Statista Market Insights cover a broad range of additional markets.

According to the estimated sales figures, RaiaDrogasil was the leading health and pharma retailer in Latin America in 2021, with **************** billion U.S. dollars. Farmacias Guadalajara and Oxxo came in second and third in the ranking, with estimated sales of *** billion U.S. dollars and *** billion U.S. dollars, respectively. Forecasts show that the ranking is expected to look similar in 2026, where the sales of RaiaDrogasil will reach to about *************** billion U.S. dollars.

The top 50 pharmaceutical companies by prescription sales in 2023 – and their research and development (R&D) spending – included big names such as Johnson & Johnson, Novartis, and AbbVie. During that year, Johnson & Johnson's Rx sales were approximately 53.5 billion U.S. dollars. Thus, the American pharma giant was both the largest pharmaceutical company based on pure pharma revenue worldwide and the second ranked pharmaceutical company based on R&D spending. Johnson & Johnson spent 14.8 billion U.S. dollars on R&D in that year.

Pharmaceutical R&D spending Research and development in the pharmaceutical industry involves the identification and development of compounds used to make new drugs. The pharmaceutical industry has the largest percentage of spending attributable to R&D among all industries. Research and development spending in the pharmaceutical industry around the world is increasing over time. However, there have been variations in the growth of research and development spending with a peak during the pandemic years 2020 and 2021.

New pharmaceutical products The goal of R&D is to produce new drugs and compounds. Globally, the U.S. pharmaceutical industry created the largest number of new drugs and compounds between 2018 and 2022, followed by Europe. Among U.S. pharmaceutical companies, there are various levels of success for new drugs depending on the phase of development. The data shows that between phase I and II alone, already over half of all drugs are failing.

The top U.S. pharmacy in 2024 by market share based on prescription drug revenue was CVS Health Corporation, followed by Walgreens Boots Alliance. CVS Health held over 25 percent of the prescription drug market revenue at that time. A significant increase in market share was reported for Cigna achieved through the acquisition of pharmacy benefit manager Express Scripts in August 2018. Before that, Cigna was mainly active in the insurance business and related products and services. CVS pharmaciesThe CVS Health Corporation is a health service company with locations all over the United States, Puerto Rico and Brazil. CVS Health comprises pharmacies, clinics and retail locations. According to recent estimates the number of CVS pharmacies has increased dramatically since 2005, however, with a downward tendency since 2021.Pharmaceutical and pharmacy marketThe U.S. has the largest single share of global pharmaceutical market revenues. The total number of prescriptions dispensed in the U.S. has increased in the last years, reaching around 6.7 billion medical prescriptions in 2022. Prescription drug expenditures have been increasing in value, while the share related to total U.S. health expenditures has remained stable in recent years. On the other hand, the pharmacy market recently saw some significant changes, especially with the growing impact of online pharmacies (mail-order pharmacies) worldwide.

In 2023, the North American region accounted for over half of the pharmaceutical market revenue worldwide. Since 2010, North America’s revenue share has increased by 11 percent, while Japan’s share has decreased by over six percent. Global pharmaceutical revenue The global pharmaceutical market made a grand total of around 1.6 trillion U.S. dollars in 2023. Worldwide pharmaceutical revenue had seen a steady increase every single year since 2001, when the market’s value was about two-thirds smaller. The largest submarket within this industry has been the United States recently. Pharma and biotech top companies The pharma industry is a large part of the healthcare branch and deals with the development and production of medical drugs. The leading pharmaceutical and biotechnological company according to the latest ranking, in terms of total revenue, was Johnson & Johnson, which generated over 85 billion U.S. dollars in revenue in 2023. Other large American companies in the top ten rankings included AbVie, Pfizer, and Merck & Co.

In 2023, Bayer México was the pharmaceutical company with the highest net sales value in Mexico, reaching around ** billion Mexican pesos. Sanofi México ranked second, with sales amounting to ** billion Mexican pesos that year. Boehringer Ingelheim México followed, with around ** billion Mexican pesos. Mexico’s pharmaceutical industryWith *** pharmaceutical manufacturing establishments operating in the country, Mexico is the nation with the second largest pharmaceutical industry in Latin America, after Brazil. In 2021, the value of Mexico's pharmaceutical market reached over ***** billion U.S. dollars, compared to the ** billion U.S. dollars for the Brazilian market. The pharma sector in Mexico relies mostly on imports. Health and pharma spending Healthcare spending in Mexico, including governmental and out-of-pocket expenditure, amounted to ***** U.S. dollars per person in 2022, a lower value compared to Costa Rica, Chile, and Colombia. Meanwhile, revenue of the OTC pharmaceutical market in the North American country amounted to *** billion U.S. dollars that year.

Unlike in the two years before, COVID-19 vaccine Comirnaty did not maintain its place as the global top ranked pharmaceutical product based on revenue. Merck's cancer drug Keytruda is the new best-selling drug worldwide, with some 25 billion U.S. dollars of revenue. Humira came in as third ranked drug in 2023, with revenues totaling 14.4 billion dollars.

Humira Humira is used mostly for the treatment of rheumatoid and psoriatic arthritis. However, like many other top drugs, the range of medical conditions it can be used to treat is much larger. Thus, the drug is also used to treat Crohn’s disease, ankylosing spondylitis, ulcerative colitis, psoriasis, uveitis, and some other autoimmune diseases. Humira is administered subcutaneously via injection. It was approved for the first time in 2002 in the United States.

Blockbuster drug reliance Blockbuster drugs often have a large impact on the manufacturer. In some cases, pharmaceutical companies are highly dependent on their sales performance. In the case of Humira, AbbVie generates over 36 percent of its total revenue from this drug and over 53 percent from its top three products. Companies that depend on a small number of blockbuster drugs could be under threat of heavy revenue loss. Biosimilars of Humira (adalimumab) are already available and will take more and more of the market in the years to come. However, Humira has exceeded the 20 billion-dollar-revenue mark in contrast to some predictions made years ago.

This statistic displays the pharmaceutical industry's market value in Europe by selected countries in 2022. The pharmaceutical market in Denmark was valued at around *** billion euros in that year. Germany was the top-ranked pharmaceutical market in Europe during that year, with a value of over ** billion euros.

This statistic depicts the top global pharmaceutical companies based on pharmaceutical revenue in 2022. In that year, Swiss corporation Novartis generated some ** billion U.S. dollars of pharmaceutical revenue. Pfizer, however, held on to the first place, still mostly due to record-breaking COVID-19 vaccine sales. Top global pharmaceutical companiesThe top pharmaceutical companies when based exclusively on prescription drug revenue with pharmaceutical products are Pfizer, AbbVie, and Johnson & Johnson, as of 2022. The companies generated ** billion U.S. dollars, ** billion U.S. dollars, and ** billion U.S. dollars, respectively, in that year. Swiss company Novartis has not maintained its top 3 ranking from previous years. Novartis is a multinational company based in Basel, Switzerland. The company was established in 1996 through the merger of Swiss pharmaceutical companies, Ciba-Geigy and Sandoz Laboratories. One of Novartis' segment consists of over-the-counter drugs such as Excedrin, sold in the United States. This is a drug normally marketed as a headache pain reliever and sold in the form of a tablet or caplet. From the United Sates, Johnson & Johnson remains one of the largest biotechnology and pharmaceutical companies as of 2022, generating some ** billion U.S. dollars in total pharmaceuticals revenue. Johnson & Johnson’s revenue from the company’s top three drugs accounted for around ** percent of the company’s total pharmaceutical revenues in 2022. In 2022, the U.S. pharma industry spent over ** billion U.S. dollars within the country on pharmaceutical research and development and nearly ** billion U.S. dollars abroad.

In 2023, Brazil was by far the Latin American country with the highest pharmaceutical market value, amounting to around **** billion U.S. dollars. Mexico ranked second, with a pharma market value of approximately **** billion U.S. dollars. As a whole, Latin America accounted for about *** percent of the global 2023 pharmaceutical market revenue. An industry driven by importsBrazil produced more than ** billion Brazilian reals worth of pharmaceutical products in 2020. Despite its significant role in the national economy, the pharmaceutical industry in this South American country relies mostly on imports. In 2021, Brazil had pharmaceutical imports for about ** billion U.S. dollars in 2021. Meanwhile, Brazil’s pharma exports have declined from **** billion U.S. dollars in 2014 to **** billion U.S. dollars in 2023. ACHE Laboratorios – a national market leaderDespite U.S companies such as Pfizer leading the global pharmaceutical industry, in Brazil Aché Laboratorios Farmacéuticos S.A. - a prominent 100-percent Brazilian pharmaceutical corporation – ranks first in the segment, with a revenue of over **** billion Brazilian reals in 2021. Focusing mostly on the production and sales of prescription drugs, the company invested more than **** billion reals in research, development, and innovation in 2018.

Johnson and Johnson is a leading international pharmaceutical company. In 2024, among its top pharmaceutical products was Darzalex which earned some **** billion U.S. dollars of revenue. Darzalex is a drug used in the treatment of multiple myeloma and light chain amyloidosis. International pharmaceutical companies There are several major pharmaceutical companies that are making significant economic impacts globally. In 2023, Johnson & Johnson, AbbVie, and Novartis were the top pharmaceutical companies based on their prescription drug sales globally. When viewed by market capitalization, Johnson and Johnson was the third ranked global pharmaceutical company, as of 2024. Top pharmaceuticals The global pharmaceutical industry showed significant growth of revenues over the past two decades. Globally, oncology, diabetes and immunology are considered the top therapeutic areas for future growth. In 2023, when covid vaccines are excluded, Humira by AbbVie, Keytruda by Merck & Co. and Ozempic by Novo Nordisk were the top drugs based on sales worldwide.

Keytruda is not only Merck & Co.’s top product, but also the best-selling drug worldwide, generating some **** billion U.S. dollars in revenue during 2024. The cancer drug with the generic name pembrolizumab increased its revenues by around *** billion U.S. dollars compared to 2023. Another of Merck’s top-ranked pharmaceuticals based on revenue is Januvia, a drug used to treat type 2 diabetes. Oncology and diabetes are two major focus areas of Merck & Co. Company backgroundMerck & Co. is a global pharmaceutical company with an interesting historical background. Originally a German company, its operations located in the U.S. were confiscated during World War I and established as a new independent American company. The rest of the company - today known as Merck KGaA – is also still active as a chemical-pharmaceutical company. Today, the American Merck is significantly larger than the German counterpart. Merck’s top product KeytrudaOver the last years, Keytruda was ranked first among the top cancer drugs worldwide based on revenue. The oncology market was for years dominated by Roche’s top products, Rituxan, Herceptin, and Avastin, as well as Celgene’s (BMS's) Revlimid. As of today, Keytruda is the global top cancer drug and is expected to keep this position for the years to come.